You are browsing the Hong Kong website, Regulated by Hong Kong SFC (CE number: BJA907). Investment is risky and you must be cautious when entering the market.
博瑞醫藥(688166.SH)擬參設蘇州鴻博基金 主投前沿生命科技、醫療健康行業
格隆匯 06-24 19:00

格隆匯 6 月 24日丨博瑞醫藥(688166.SH)公佈,為了配合公司的戰略發展規劃,促進公司在前沿生命科技領域的戰略佈局,通過獲得、持有和處置生命科學相關產業的科技型企業之股權,拓展公司投資渠道,獲取投資收益,2020年6月24日,公司與北京文資數碼投資管理有限公司、北京鴻瀚投資基金管理中心(有限合夥)簽訂《蘇州鴻博創業投資合夥企業(有限合夥)之合夥協議》,共同設立蘇州鴻博創業投資合夥企業(有限合夥)(以工商登記部門最終核准的名稱為準,“蘇州鴻博基金”或“投資基金”)。

蘇州鴻博基金募集規模為3億元人民幣,其中博瑞醫藥作為有限合夥人,認繳出資額為9000萬元人民幣,以公司自有資金投入。蘇州鴻博基金將主要投資前沿生命科技、醫療健康行業。

公司此次對外投資是在保證公司主營業務正常發展的前提下作出的投資決策,不會對公司現有業務開展造成資金壓力,不會影響公司生產經營活動的正常運行。藉助專業投資機構的投資管理經驗和風險控制體系,可為公司的健康可持續發展提供保障,不存在損害上市公司及全體股東利益的情形。

蘇州鴻博基金根據合夥協議約定從事生命科學相關企業的投資業務,通過此次投資,有利於公司藉助專業機構的投資能力挖掘並儲備優質項目,滿足公司業務拓展和戰略發展。

Follow us
Find us on Facebook, Twitter , Instagram, and YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!
Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.
uSMART
Wealth Growth Made Easy
Open Account